Career
| Since 2020 | Chairman Comprehensive Cancer Center Zurich |
|---|---|
| 2018-2020 | Chairman Swiss Society of Hematology |
| Since 2018 | Chairman and Director of the Clinic for Medical Oncology and Hematology University Hospital Zurich |
| Since 2010 | Professor with the right to confer a doctorate at the Faculty of Mathematics and Natural Sciences of the University of Zurich |
| Since 2009 | Professor/Ordinarius of Hematology at the Faculty of Medicine and Director of Hematology at the University and University Hospital Zurich |
| 2009 | Specialist in Hematology (FMH) |
| 2009 | Specialist in Internal Medicine (FMH) |
| 2007 | Habilitation (Venia Legendi in Internal Medicine), Medical Faculty of the University of Tübingen, Germany |
| 2007 | Specialist in Hematology and Oncology, Germany/European Union |
| 2006 | Specialist in Internal Medicine, Germany/European Union |
| 2002-2009 | Research Group Leader, Institute for Research in Biomedicine (IRB), Switzerland; Continuing Medical Education in Internal Medicine and Hematology and Oncology, University Hospital Tübingen, Germany, and Swiss-Italian Institute for Oncology (IOSI), Bellinzona |
| 1999-2002 | Postdoctoral Research Fellow, Stanford University |
| 1995-1999 | Clinical Training Internal Medicine and Hematology and Oncology, University Hospital Tübingen |
| 1996 | Dissertation University of Tübingen |
| 1995 | State Examination University of Tübingen |
Most important memberships
- Swiss Society for Hematology
- Association of Swiss Physicians(FMH)
- Swiss Society of Allergology and Immunology (SSAI)
- Swiss Stem Cell Network (SSCN)
- German Society for Hematology and Medical Oncology (DGHO)
- European Society of Hematology (EHA)
- American Society of Hematology (ASH)
- International Society of Experimental Hematology (ISEH)
- Henry Kunkel Society (HKS)
- Charles Rodolphe Brupbacher Foundation (scientific committee)
- Helmut Horten Foundation (scientific committee)
Research focus
- Hematopoietic stem cells, hematopoiesis, hematopoietic aging.
- Hematopoietic stem cell malignancies (AML, MDS, MPN)
- Immunotherapy of cancer